These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Small molecule inhibitors of anthrax toxin-induced cytotoxicity targeted against protective antigen. Rubert Pérez C; López-Pérez D; Chmielewski J; Lipton M Chem Biol Drug Des; 2012 Mar; 79(3):260-9. PubMed ID: 22146079 [TBL] [Abstract][Full Text] [Related]
5. Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. Zomber G; Reuveny S; Garti N; Shafferman A; Elhanany E J Biol Chem; 2005 Dec; 280(48):39897-906. PubMed ID: 16188881 [TBL] [Abstract][Full Text] [Related]
6. Anthrax protective antigen cleavage and clearance from the blood of mice and rats. Moayeri M; Wiggins JF; Leppla SH Infect Immun; 2007 Nov; 75(11):5175-84. PubMed ID: 17724066 [TBL] [Abstract][Full Text] [Related]
7. Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Brossier F; Sirard JC; Guidi-Rontani C; Duflot E; Mock M Infect Immun; 1999 Feb; 67(2):964-7. PubMed ID: 9916116 [TBL] [Abstract][Full Text] [Related]
8. Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism. Kintzer AF; Sterling HJ; Tang II; Williams ER; Krantz BA PLoS One; 2010 Nov; 5(11):e13888. PubMed ID: 21079738 [TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Smith K; Crowe SR; Garman L; Guthridge CJ; Muther JJ; McKee E; Zheng NY; Farris AD; Guthridge JM; Wilson PC; James JA Vaccine; 2012 Jun; 30(28):4276-83. PubMed ID: 22425791 [TBL] [Abstract][Full Text] [Related]
10. Lethal factor of anthrax toxin binds monomeric form of protective antigen. Chvyrkova I; Zhang XC; Terzyan S Biochem Biophys Res Commun; 2007 Aug; 360(3):690-5. PubMed ID: 17617379 [TBL] [Abstract][Full Text] [Related]
11. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Brossier F; Lévy M; Landier A; Lafaye P; Mock M Infect Immun; 2004 Nov; 72(11):6313-7. PubMed ID: 15501759 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of lethal toxin neutralization by a human monoclonal antibody specific for the PA(20) region of Bacillus anthracis protective antigen. Reason D; Liberato J; Sun J; Camacho J; Zhou J Toxins (Basel); 2011 Aug; 3(8):979-90. PubMed ID: 22069752 [TBL] [Abstract][Full Text] [Related]
13. Identification of small molecule inhibitors of anthrax lethal factor. Panchal RG; Hermone AR; Nguyen TL; Wong TY; Schwarzenbacher R; Schmidt J; Lane D; McGrath C; Turk BE; Burnett J; Aman MJ; Little S; Sausville EA; Zaharevitz DW; Cantley LC; Liddington RC; Gussio R; Bavari S Nat Struct Mol Biol; 2004 Jan; 11(1):67-72. PubMed ID: 14718925 [TBL] [Abstract][Full Text] [Related]
14. Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity. Panchal RG; Halverson KM; Ribot W; Lane D; Kenny T; Abshire TG; Ezzell JW; Hoover TA; Powell B; Little S; Kasianowicz JJ; Bavari S J Biol Chem; 2005 Mar; 280(11):10834-9. PubMed ID: 15644338 [TBL] [Abstract][Full Text] [Related]
15. Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design. Karginov VA; Nestorovich EM; Moayeri M; Leppla SH; Bezrukov SM Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15075-80. PubMed ID: 16214885 [TBL] [Abstract][Full Text] [Related]
18. Anthrax lethal factor inhibitors as potential countermeasure of the infection. Kumar BV; Malik S; Grandhi P; Dayam R; Sarma JA Curr Top Med Chem; 2014; 14(17):1977-89. PubMed ID: 25262802 [TBL] [Abstract][Full Text] [Related]
19. Cross-inhibition between furin and lethal factor inhibitors. Peinado JR; Kacprzak MM; Leppla SH; Lindberg I Biochem Biophys Res Commun; 2004 Aug; 321(3):601-5. PubMed ID: 15358148 [TBL] [Abstract][Full Text] [Related]
20. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates. Yan M; Roehrl MH; Basar E; Wang JY Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]